{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T01:12:32Z","timestamp":1790730752975,"version":"4.1.0"},"reference-count":233,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T00:00:00Z","timestamp":1765152000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Research Fund\u2014Flanders","award":["11B2323N"],"award-info":[{"award-number":["11B2323N"]}]},{"name":"Research Fund\u2014Flanders","award":["11B2325N"],"award-info":[{"award-number":["11B2325N"]}]},{"name":"Bijzondere Onderzoeksfonds UGent","award":["01D07923"],"award-info":[{"award-number":["01D07923"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Glioblastoma (GBM) is the most aggressive primary brain tumor, characterized by rapid progression, extensive inter- and intra-tumoral heterogeneity, and resistance to standard-of-care, including radiotherapy. Radiotherapy remains a cornerstone of GBM management, but its efficacy is limited by complex tumor biology and mechanisms of radioresistance. This review explores the advances in radiotherapy for GBM, focusing on the interplay between tumor biology and emerging treatment strategies. Hallmarks of GBM biology, including hypoxia, the robust DNA repair mechanisms, the immunosuppressive tumor microenvironment (TME), and the extensive plasticity contribute to therapeutic resistance. Innovative approaches in radiotherapy may allow to address these challenges. Charged particle therapies (CPTs), including proton and carbon ion therapy, offer superior precision and enhanced biological effectiveness by delivering lethal doses to tumor cells while sparing surrounding healthy tissue. FLASH therapy, using ultra-high dose rates, could reduce normal tissue toxicity without compromising tumor control. Furthermore, targeted radionuclide therapy harnesses tumor-specific targets to systemically deliver radiopharmaceuticals carrying therapeutic radionuclides directly to cancer cells, improving specificity and reducing off-target effects. This review highlights the promise of these novel radiotherapy modalities to address GBM\u2019s inherent heterogeneity and treatment resistance. By integrating advancements in technology with novel insights into GBM biology, these approaches may significantly improve patient outcomes.<\/jats:p>","DOI":"10.1093\/noajnl\/vdaf255","type":"journal-article","created":{"date-parts":[[2025,12,7]],"date-time":"2025-12-07T12:43:48Z","timestamp":1765111428000},"source":"Crossref","is-referenced-by-count":5,"title":["Innovative radiotherapies for the treatment of glioblastoma"],"prefix":"10.1093","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1792-2066","authenticated-orcid":false,"given":"Lou","family":"Van Eupen","sequence":"first","affiliation":[{"name":"Nuclear Medical Applications Institute, Belgian Nuclear Research Centre (SCK CEN) , Mol,","place":["Belgium"]},{"name":"Laboratory for Precision Cancer Medicine, Katholieke Universiteit Leuven , Leuven, (L.V.E.)","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3981-053X","authenticated-orcid":false,"given":"Anthony","family":"Waked","sequence":"additional","affiliation":[{"name":"Nuclear Medical Applications Institute, Belgian Nuclear Research Centre (SCK CEN) , Mol,","place":["Belgium"]},{"name":"Laboratory of Nervous System Disorders and Therapy, GIGA Neurosciences, Universit\u00e9 de Li\u00e8ge , Li\u00e8ge,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7989-5027","authenticated-orcid":false,"given":"Irina","family":"Primac","sequence":"additional","affiliation":[{"name":"Nuclear Medical Applications Institute, Belgian Nuclear Research Centre (SCK CEN) , Mol,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2048-6530","authenticated-orcid":false,"given":"Koen","family":"Vermeulen","sequence":"additional","affiliation":[{"name":"Nuclear Medical Applications Institute, Belgian Nuclear Research Centre (SCK CEN) , Mol,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1274-0765","authenticated-orcid":false,"given":"Isabeau","family":"De Bie","sequence":"additional","affiliation":[{"name":"Nuclear Medical Applications Institute, Belgian Nuclear Research Centre (SCK CEN) , Mol,","place":["Belgium"]},{"name":"4Brain Lab, Universiteit Gent , Ghent,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8985-1578","authenticated-orcid":false,"given":"Mohammed Abderrafi","family":"Benotmane","sequence":"additional","affiliation":[{"name":"Nuclear Medical Applications Institute, Belgian Nuclear Research Centre (SCK CEN) , Mol,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4359-3403","authenticated-orcid":false,"given":"Roel","family":"Quintens","sequence":"additional","affiliation":[{"name":"Nuclear Medical Applications Institute, Belgian Nuclear Research Centre (SCK CEN) , Mol,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,12,8]]},"reference":[{"key":"2026041704180186400_vdaf255-B1","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of tumors of the central nervous system: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol"},{"key":"2026041704180186400_vdaf255-B2","first-page":"1","volume-title":"Glioblastoma Resistance to Chemotherapy: Molecular Mechanisms and Innovative Reversal Strategies","author":"Ludwig","year":"2021"},{"key":"2026041704180186400_vdaf255-B3","first-page":"126","author":"Horak","year":"2022"},{"key":"2026041704180186400_vdaf255-B4","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1093\/neuonc\/noab269","article-title":"Cancer cell heterogeneity and plasticity: a paradigm shift in glioblastoma","volume":"24","author":"Yabo","year":"2022","journal-title":"Neuro Oncol"},{"key":"2026041704180186400_vdaf255-B5","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.stem.2019.11.015","article-title":"Outer radial glia-like cancer stem cells contribute to heterogeneity of glioblastoma","volume":"26","author":"Bhaduri","year":"2020","journal-title":"Cell Stem Cell"},{"key":"2026041704180186400_vdaf255-B6","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1038\/s41467-020-17186-5","article-title":"Single-cell RNA-seq reveals that glioblastoma recapitulates a normal neurodevelopmental hierarchy","volume":"11","author":"Couturier","year":"2020","journal-title":"Nat Commun"},{"key":"2026041704180186400_vdaf255-B7","doi-asserted-by":"crossref","first-page":"e1543","DOI":"10.1038\/cddis.2014.509","article-title":"Ionizing radiations sustain glioblastoma cell dedifferentiation to a stem-like phenotype through survivin: possible involvement in radioresistance","volume":"5","author":"Dahan","year":"2014","journal-title":"Cell Death Dis"},{"key":"2026041704180186400_vdaf255-B8","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ccell.2017.06.003","article-title":"Tumor evolution of glioma-intrinsic gene expression subtypes associates with immunological changes in the microenvironment","volume":"32","author":"Wang","year":"2017","journal-title":"Cancer Cell"},{"key":"2026041704180186400_vdaf255-B9","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.cell.2019.06.024","article-title":"An integrative model of cellular states, plasticity, and genetics for glioblastoma","volume":"178","author":"Neftel","year":"2019","journal-title":"Cell"},{"key":"2026041704180186400_vdaf255-B10","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ccr.2009.12.020","article-title":"Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1","volume":"17","author":"Verhaak","year":"2010","journal-title":"Cancer Cell"},{"key":"2026041704180186400_vdaf255-B11","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1126\/science.1254257","article-title":"Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma","volume":"344","author":"Patel","year":"2014","journal-title":"Science"},{"key":"2026041704180186400_vdaf255-B12","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s43018-020-00159-4","article-title":"Pathway-based classification of glioblastoma uncovers a mitochondrial subtype with therapeutic vulnerabilities","volume":"2","author":"Garofano","year":"2021","journal-title":"Nat Cancer"},{"key":"2026041704180186400_vdaf255-B13","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/s43018-020-00150-z","article-title":"Single-cell analyses reveal YAP\/TAZ as regulators of stemness and cell plasticity in glioblastoma","volume":"2","author":"Castellan","year":"2021","journal-title":"Nat Cancer"},{"key":"2026041704180186400_vdaf255-B14","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/s43018-020-00154-9","article-title":"Gradient of developmental and injury response transcriptional states defines functional vulnerabilities underpinning glioblastoma heterogeneity","volume":"2","author":"Richards","year":"2021","journal-title":"Nat Cancer"},{"key":"2026041704180186400_vdaf255-B15","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1016\/j.cell.2024.03.029","article-title":"Integrative spatial analysis reveals a multi-layered organization of glioblastoma","volume":"187","author":"Greenwald","year":"2024","journal-title":"Cell"},{"key":"2026041704180186400_vdaf255-B16","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1038\/s41588-025-02167-5","article-title":"The multilayered transcriptional architecture of glioblastoma ecosystems","volume":"57","author":"Nomura","year":"2025","journal-title":"Nat Genet"},{"key":"2026041704180186400_vdaf255-B17","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.3390\/ijms20112746","article-title":"Proneural-mesenchymal transition: phenotypic plasticity to acquire multitherapy resistance in glioblastoma","volume":"20","author":"Fedele","year":"2019","journal-title":"Int J Mol Sci"},{"key":"2026041704180186400_vdaf255-B18","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med"},{"key":"2026041704180186400_vdaf255-B19","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1038\/sj.bjc.6600827","article-title":"Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules","volume":"88","author":"Tolcher","year":"2003","journal-title":"Br J Cancer"},{"key":"2026041704180186400_vdaf255-B20","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3892\/ijo.2022.5359","article-title":"Signaling pathways and therapeutic approaches in glioblastoma multiforme (review)","volume":"60","author":"Khabibov","year":"2022","journal-title":"Int J Oncol"},{"key":"2026041704180186400_vdaf255-B21","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1093\/neuonc\/noae072","article-title":"DNA damage response in brain tumors: a society for neuro-oncology consensus review on mechanisms and translational efforts in neuro-oncology","volume":"26","author":"Rahman","year":"2024","journal-title":"Neuro Oncol"},{"key":"2026041704180186400_vdaf255-B22","doi-asserted-by":"crossref","first-page":"109663","DOI":"10.1016\/j.radonc.2023.109663","article-title":"ESTRO-EANO guideline on target delineation and radiotherapy details for glioblastoma","volume":"184","author":"Niyazi","year":"2023","journal-title":"Radiother Oncol"},{"key":"2026041704180186400_vdaf255-B23","volume-title":"Radiation Therapy of Tumors and Diseases of the Nervous System. Philadelphia","author":"Bouchard","year":"1966"},{"key":"2026041704180186400_vdaf255-B24","doi-asserted-by":"crossref","first-page":"333","DOI":"10.3171\/jns.1978.49.3.0333","article-title":"Evaluation of BCNU and\/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial","volume":"49","author":"Walker","year":"1978","journal-title":"J Neurosurg"},{"key":"2026041704180186400_vdaf255-B25","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1016\/0360-3016(79)90553-4","article-title":"An analysis of dose-effect relationship in the radiotherapy of malignant gliomas","volume":"5","author":"Walker","year":"1979","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026041704180186400_vdaf255-B26","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/s41571-020-00447-z","article-title":"EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood","volume":"18","author":"Weller","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"2026041704180186400_vdaf255-B27","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.clon.2016.09.015","article-title":"Radiotherapy in glioblastoma: the past, the present and the future","volume":"29","author":"Gzell","year":"2017","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"2026041704180186400_vdaf255-B28","doi-asserted-by":"crossref","first-page":"748","DOI":"10.3389\/fneur.2017.00748","article-title":"Advances in radiotherapy for glioblastoma","volume":"8","author":"Mann","year":"2017","journal-title":"Front Neurol"},{"key":"2026041704180186400_vdaf255-B29","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1056\/NEJMoa065901","article-title":"Radiotherapy for glioblastoma in the elderly","volume":"356","author":"Keime-Guibert","year":"2007","journal-title":"N Engl J Med"},{"key":"2026041704180186400_vdaf255-B30","doi-asserted-by":"crossref","DOI":"10.1093\/neuonc\/noaf158","article-title":"Assessing time-trend bias in glioblastoma prognosis over 2 decades of clinical trials","author":"Sferruzza","year":"2025","journal-title":"Neuro Oncol"},{"key":"2026041704180186400_vdaf255-B31","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1093\/neuonc\/noaf134","article-title":"Improvements in survival for glioblastoma in the post-Stupp protocol era","volume":"27","author":"Price","year":"2025","journal-title":"Neuro Oncol"},{"key":"2026041704180186400_vdaf255-B32","first-page":"158","article-title":"Long-term trends in glioblastoma survival: implications for historical control groups in clinical trials","volume":"7","author":"Sheikh","year":"2020","journal-title":"Neurooncol Pract"},{"key":"2026041704180186400_vdaf255-B33","first-page":"5821","article-title":"Identification of a cancer stem cell in human brain tumors","volume":"63","author":"Singh","year":"2003","journal-title":"Cancer Res"},{"key":"2026041704180186400_vdaf255-B34","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.1016\/j.neuron.2024.11.012","article-title":"Give me a sign(ature): converging on the CSC of glioblastoma","volume":"112","author":"Patel","year":"2024","journal-title":"Neuron"},{"key":"2026041704180186400_vdaf255-B35","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/s41586-018-0389-3","article-title":"Human glioblastoma arises from subventricular zone cells with low-level driver mutations","volume":"560","author":"Lee","year":"2018","journal-title":"Nature"},{"key":"2026041704180186400_vdaf255-B36","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1172\/JCI89587","article-title":"Overcoming therapeutic resistance in glioblastoma: the way forward","volume":"127","author":"Osuka","year":"2017","journal-title":"J Clin Invest"},{"key":"2026041704180186400_vdaf255-B37","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1038\/s41467-019-09853-z","article-title":"Stem cell-associated heterogeneity in glioblastoma results from intrinsic tumor plasticity shaped by the microenvironment","volume":"10","author":"Dirkse","year":"2019","journal-title":"Nat Commun"},{"key":"2026041704180186400_vdaf255-B38","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/nature05236","article-title":"Glioma stem cells promote radioresistance by preferential activation of the DNA damage response","volume":"444","author":"Bao","year":"2006","journal-title":"Nature"},{"key":"2026041704180186400_vdaf255-B39","doi-asserted-by":"crossref","first-page":"310","DOI":"10.3171\/2010.2.JNS091607","article-title":"Accumulation of CD133-positive glioma cells after high-dose irradiation by Gamma Knife surgery plus external beam radiation: Clinical article","volume":"113","author":"Tamura","year":"2010","journal-title":"J Neurosurg"},{"key":"2026041704180186400_vdaf255-B40","doi-asserted-by":"crossref","first-page":"E9086","DOI":"10.1073\/pnas.1708122114","article-title":"PAF promotes stemness and radioresistance of glioma stem cells","volume":"114","author":"Ong","year":"2017","journal-title":"Proc Natl Acad Sci USA"},{"key":"2026041704180186400_vdaf255-B41","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1186\/s12885-016-2647-9","article-title":"A radiosensitizing effect of RAD51 inhibition in glioblastoma stem-like cells","volume":"16","author":"Balbous","year":"2016","journal-title":"BMC Cancer"},{"key":"2026041704180186400_vdaf255-B42","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.stemcr.2016.12.005","article-title":"RAD51 is a selective DNA repair target to radiosensitize glioma stem cells","volume":"8","author":"King","year":"2017","journal-title":"Stem Cell Reports"},{"key":"2026041704180186400_vdaf255-B43","doi-asserted-by":"crossref","first-page":"550","DOI":"10.15252\/emmm.201505890","article-title":"MET inhibition overcomes radiation resistance of glioblastoma stem-like cells","volume":"8","author":"De Bacco","year":"2016","journal-title":"EMBO Mol Med"},{"key":"2026041704180186400_vdaf255-B44","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/j.ijrobp.2008.07.031","article-title":"Replication-dependent radiosensitization of human glioma cells by inhibition of poly(ADP-Ribose) polymerase: mechanisms and therapeutic potential","volume":"72","author":"Dungey","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026041704180186400_vdaf255-B45","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/cdd.2013.136","article-title":"Therapeutic targeting of constitutive PARP activation compromises stem cell phenotype and survival of glioblastoma-initiating cells","volume":"21","author":"Venere","year":"2014","journal-title":"Cell Death Differ"},{"key":"2026041704180186400_vdaf255-B46","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1038\/labinvest.2011.161","article-title":"Wnt activation is implicated in glioblastoma radioresistance","volume":"92","author":"Kim","year":"2012","journal-title":"Lab Invest"},{"key":"2026041704180186400_vdaf255-B47","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/stem.261","article-title":"Notch promotes radioresistance of glioma stem cells","volume":"28","author":"Wang","year":"2010","journal-title":"Stem Cells"},{"key":"2026041704180186400_vdaf255-B48","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1002\/stem.429","article-title":"Inhibition of notch signaling in glioblastoma targets cancer stem cells via an endothelial cell intermediate","volume":"28","author":"Hovinga","year":"2010","journal-title":"Stem Cells"},{"key":"2026041704180186400_vdaf255-B49","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.stemcr.2014.12.006","article-title":"EZH2 protects glioma stem cells from radiation-induced cell death in a MELK\/FOXM1-dependent manner","volume":"4","author":"Kim","year":"2015","journal-title":"Stem Cell Rep"},{"key":"2026041704180186400_vdaf255-B50","doi-asserted-by":"crossref","first-page":"e0137703","DOI":"10.1371\/journal.pone.0137703","article-title":"FoxM1 promotes stemness and radio-resistance of glioblastoma by regulating the master stem cell regulator Sox2","volume":"10","author":"Lee","year":"2015","journal-title":"PLoS One"},{"key":"2026041704180186400_vdaf255-B51","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41586-019-1775-1","article-title":"Longitudinal molecular trajectories of diffuse glioma in adults","volume":"576","author":"Barthel","year":"2019","journal-title":"Nature"},{"key":"2026041704180186400_vdaf255-B52","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.ccell.2019.02.007","article-title":"Evolutionary trajectories of IDH(WT) glioblastomas reveal a common path of early tumorigenesis instigated years ahead of initial diagnosis","volume":"35","author":"K\u00f6rber","year":"2019","journal-title":"Cancer Cell"},{"key":"2026041704180186400_vdaf255-B53","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1093\/neuonc\/noy020","article-title":"Glioma through the looking GLASS: molecular evolution of diffuse gliomas and the glioma longitudinal AnalySiS consortium","volume":"20","author":"Aldape","year":"2018","journal-title":"Neuro Oncol"},{"key":"2026041704180186400_vdaf255-B54","doi-asserted-by":"crossref","first-page":"4009","DOI":"10.1073\/pnas.1219747110","article-title":"Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics","volume":"110","author":"Sottoriva","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"2026041704180186400_vdaf255-B55","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.ccell.2015.07.013","article-title":"Spatiotemporal evolution of the primary glioblastoma genome","volume":"28","author":"Kim","year":"2015","journal-title":"Cancer Cell"},{"key":"2026041704180186400_vdaf255-B56","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.celrep.2018.03.107","article-title":"A distinct DNA methylation shift in a subset of glioma CpG island methylator phenotypes during tumor recurrence","volume":"23","author":"de Souza","year":"2018","journal-title":"Cell Rep"},{"key":"2026041704180186400_vdaf255-B57","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/s41586-020-2209-9","article-title":"Mechanisms and therapeutic implications of hypermutation in gliomas","volume":"580","author":"Touat","year":"2020","journal-title":"Nature"},{"key":"2026041704180186400_vdaf255-B58","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/s41580-020-0237-9","article-title":"Guidelines and definitions for research on epithelial\u2013mesenchymal transition","volume":"21","author":"Yang","year":"2020","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2026041704180186400_vdaf255-B59","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1038\/s41586-024-07690-9","article-title":"Cellular adaptation to cancer therapy along a resistance continuum","volume":"631","author":"Fran\u00e7a","year":"2024","journal-title":"Nature"},{"key":"2026041704180186400_vdaf255-B60","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/nature08712","article-title":"The transcriptional network for mesenchymal transformation of brain tumours","volume":"463","author":"Carro","year":"2010","journal-title":"Nature"},{"key":"2026041704180186400_vdaf255-B61","doi-asserted-by":"crossref","first-page":"8644","DOI":"10.1073\/pnas.1221478110","article-title":"Mesenchymal glioma stem cells are maintained by activated glycolytic metabolism involving aldehyde dehydrogenase 1A3","volume":"110","author":"Mao","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"2026041704180186400_vdaf255-B62","doi-asserted-by":"crossref","first-page":"5248","DOI":"10.1073\/pnas.1321014111","article-title":"In vivo radiation response of proneural glioma characterized by protective p53 transcriptional program and proneural-mesenchymal shift","volume":"111","author":"Halliday","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"key":"2026041704180186400_vdaf255-B63","doi-asserted-by":"crossref","first-page":"4302","DOI":"10.1158\/0008-5472.CAN-14-3331","article-title":"STAT3 blockade inhibits radiation-induced malignant progression in glioma","volume":"75","author":"Lau","year":"2015","journal-title":"Cancer Res"},{"key":"2026041704180186400_vdaf255-B64","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1016\/j.celrep.2019.01.076","article-title":"Phenotypic plasticity of invasive edge glioma stem-like cells in response to ionizing radiation","volume":"26","author":"Minata","year":"2019","journal-title":"Cell Rep"},{"key":"2026041704180186400_vdaf255-B65","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.1016\/j.celrep.2016.11.056","article-title":"Clonal variation in drug and radiation response among glioma-initiating cells is linked to proneural-mesenchymal transition","volume":"17","author":"Segerman","year":"2016","journal-title":"Cell Rep"},{"key":"2026041704180186400_vdaf255-B66","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1038\/s43018-022-00475-x","article-title":"A single-cell atlas of glioblastoma evolution under therapy reveals cell-intrinsic and cell-extrinsic therapeutic targets","volume":"3","author":"Wang","year":"2022","journal-title":"Nat Cancer"},{"key":"2026041704180186400_vdaf255-B67","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.ccell.2023.12.015","article-title":"Integrated proteogenomic characterization of glioblastoma evolution","volume":"42","author":"Kim","year":"2024","journal-title":"Cancer Cell"},{"key":"2026041704180186400_vdaf255-B68","doi-asserted-by":"crossref","first-page":"3602","DOI":"10.1038\/s41467-024-47985-z","article-title":"VC-resist glioblastoma cell state: vessel co-option as a key driver of chemoradiation resistance","volume":"15","author":"Pichol-Thievend","year":"2024","journal-title":"Nat Commun"},{"key":"2026041704180186400_vdaf255-B69","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s00018-023-04772-1","article-title":"Single-cell molecular profiling using ex vivo functional readouts fuels precision oncology in glioblastoma","volume":"80","author":"Panovska","year":"2023","journal-title":"Cell Mol Life Sci"},{"key":"2026041704180186400_vdaf255-B70","doi-asserted-by":"crossref","first-page":"6202","DOI":"10.1038\/s41467-022-33943-0","article-title":"P300 promotes tumor recurrence by regulating radiation-induced conversion of glioma stem cells to vascular-like cells","volume":"13","author":"Muthukrishnan","year":"2022","journal-title":"Nat Commun"},{"key":"2026041704180186400_vdaf255-B71","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.ccell.2022.05.009","article-title":"Spatially resolved multi-omics deciphers bidirectional tumor-host interdependence in glioblastoma","volume":"40","author":"Ravi","year":"2022","journal-title":"Cancer Cell"},{"key":"2026041704180186400_vdaf255-B72","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.trecan.2015.10.009","article-title":"Glioblastoma: defining tumor niches","volume":"1","author":"Hambardzumyan","year":"2015","journal-title":"Trends Cancer"},{"key":"2026041704180186400_vdaf255-B73","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.3390\/cancers12092511","article-title":"Radioresistance in glioblastoma\u00a0and\u00a0the development of radiosensitizers","volume":"12","author":"Ali","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2026041704180186400_vdaf255-B74","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1186\/s13287-021-02231-x","article-title":"Role of glioblastoma stem cells in cancer therapeutic resistance: a perspective on antineoplastic agents from natural sources and chemical derivatives","volume":"12","author":"Alves","year":"2021","journal-title":"Stem Cell Res Ther"},{"key":"2026041704180186400_vdaf255-B75","first-page":"vdad009","article-title":"Tumor microenvironment in glioblastoma: current and emerging concepts","volume":"5","author":"Sharma","year":"2023","journal-title":"Neurooncol Adv"},{"key":"2026041704180186400_vdaf255-B76","article-title":"Adapt to persist: glioblastoma microenvironment and epigenetic regulation on cell plasticity","volume":"11","author":"Uribe","year":"2022","journal-title":"Biology (Basel)"},{"key":"2026041704180186400_vdaf255-B77","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/bjc.1955.55","article-title":"The histological structure of some human lung cancers and the possible implications for radiotherapy","volume":"9","author":"Thomlinson","year":"1955","journal-title":"Br J Cancer"},{"key":"2026041704180186400_vdaf255-B78","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.ebiom.2019.03.064","article-title":"Gene signatures of quiescent glioblastoma cells reveal mesenchymal shift and interactions with niche microenvironment","volume":"42","author":"Tejero","year":"2019","journal-title":"EBioMedicine"},{"key":"2026041704180186400_vdaf255-B79","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.canlet.2015.01.010","article-title":"Hypoxia enhances migration and invasion in glioblastoma by promoting a mesenchymal shift mediated by the HIF1\u03b1\u2013ZEB1 axis","volume":"359","author":"Joseph","year":"2015","journal-title":"Cancer Lett"},{"key":"2026041704180186400_vdaf255-B80","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.wneu.2015.12.032","article-title":"The impact of hypoxia and mesenchymal transition on glioblastoma pathogenesis and cancer stem cells regulation","volume":"88","author":"Karsy","year":"2016","journal-title":"World Neurosurg"},{"key":"2026041704180186400_vdaf255-B81","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1158\/2159-8290.CD-20-0219","article-title":"Phenotypic mapping of pathologic cross-talk between glioblastoma and innate immune cells by synthetic genetic tracing","volume":"11","author":"Schmitt","year":"2021","journal-title":"Cancer Discov"},{"key":"2026041704180186400_vdaf255-B82","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/nature16071","article-title":"Brain tumour cells interconnect to a functional and resistant network","volume":"528","author":"Osswald","year":"2015","journal-title":"Nature"},{"key":"2026041704180186400_vdaf255-B83","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/s41586-019-1564-x","article-title":"Glutamatergic synaptic input to glioma cells drives brain tumour progression","volume":"573","author":"Venkataramani","year":"2019","journal-title":"Nature"},{"key":"2026041704180186400_vdaf255-B84","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/s41586-019-1563-y","article-title":"Electrical and synaptic integration of glioma into neural circuits","volume":"573","author":"Venkatesh","year":"2019","journal-title":"Nature"},{"key":"2026041704180186400_vdaf255-B85","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/s43018-023-00556-5","article-title":"GAP43-dependent mitochondria transfer from astrocytes enhances glioblastoma tumorigenicity","volume":"4","author":"Watson","year":"2023","journal-title":"Nat Cancer"},{"key":"2026041704180186400_vdaf255-B86","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1016\/j.cell.2022.06.033","article-title":"Invasive glioma cells: the malignant pioneers that follow the current","volume":"185","author":"Taylor","year":"2022","journal-title":"Cell"},{"key":"2026041704180186400_vdaf255-B87","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1016\/j.cell.2022.06.054","article-title":"Glioblastoma hijacks neuronal mechanisms for brain invasion","volume":"185","author":"Venkataramani","year":"2022","journal-title":"Cell"},{"key":"2026041704180186400_vdaf255-B88","doi-asserted-by":"crossref","first-page":"4660","DOI":"10.1038\/s41467-020-18189-y","article-title":"Glioma-initiating cells at tumor edge gain signals from tumor core cells to promote their malignancy","volume":"11","author":"Bastola","year":"2020","journal-title":"Nat Commun"},{"key":"2026041704180186400_vdaf255-B89","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.stem.2018.03.011","article-title":"Reciprocal signaling between glioblastoma stem cells and differentiated tumor cells promotes malignant progression","volume":"22","author":"Wang","year":"2018","journal-title":"Cell Stem Cell"},{"key":"2026041704180186400_vdaf255-B90","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ccell.2018.05.012","article-title":"Apoptotic cell-derived extracellular vesicles promote malignancy of glioblastoma via intercellular transfer of splicing factors","volume":"34","author":"Pavlyukov","year":"2018","journal-title":"Cancer Cell"},{"key":"2026041704180186400_vdaf255-B91","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.ccr.2013.08.001","article-title":"Mesenchymal differentiation mediated by NF-kappaB promotes radiation resistance in glioblastoma","volume":"24","author":"Bhat","year":"2013","journal-title":"Cancer Cell"},{"key":"2026041704180186400_vdaf255-B92","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.ccell.2021.05.002","article-title":"Interactions between cancer cells and immune cells drive transitions to mesenchymal-like states in glioblastoma","volume":"39","author":"Hara","year":"2021","journal-title":"Cancer Cell"},{"key":"2026041704180186400_vdaf255-B93","doi-asserted-by":"crossref","first-page":"eadf1332","DOI":"10.1126\/sciadv.adf1332","article-title":"Human cerebrospinal fluid affects chemoradiotherapy sensitivities in tumor cells from patients with glioblastoma","volume":"9","author":"Stringer","year":"2023","journal-title":"Sci Adv"},{"key":"2026041704180186400_vdaf255-B94","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/nrc3958","article-title":"The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence","volume":"15","author":"Barker","year":"2015","journal-title":"Nat Rev Cancer"},{"key":"2026041704180186400_vdaf255-B95","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.stem.2016.11.003","article-title":"Adaptive chromatin remodeling drives glioblastoma stem cell plasticity and drug tolerance","volume":"20","author":"Liau","year":"2017","journal-title":"Cell Stem Cell"},{"key":"2026041704180186400_vdaf255-B96","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1186\/s13059-020-02085-1","article-title":"Single-cell lineage analysis reveals genetic and epigenetic interplay in glioblastoma drug resistance","volume":"21","author":"Eyler","year":"2020","journal-title":"Genome Biol"},{"key":"2026041704180186400_vdaf255-B97","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/j.ccell.2023.06.007","article-title":"Tissue factor is a critical regulator of radiation therapy-induced glioblastoma remodeling","volume":"41","author":"Jeon","year":"2023","journal-title":"Cancer Cell"},{"key":"2026041704180186400_vdaf255-B98","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.cell.2019.11.036","article-title":"A patient-derived glioblastoma organoid model and biobank recapitulates inter- and intra-tumoral heterogeneity","volume":"180","author":"Jacob","year":"2020","journal-title":"Cell"},{"key":"2026041704180186400_vdaf255-B99","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1016\/j.celrep.2018.03.105","article-title":"Glioblastoma model using human cerebral organoids","volume":"23","author":"Ogawa","year":"2018","journal-title":"Cell Rep"},{"key":"2026041704180186400_vdaf255-B100","doi-asserted-by":"crossref","first-page":"3203","DOI":"10.1016\/j.celrep.2019.02.063","article-title":"Modeling patient-derived glioblastoma with cerebral organoids","volume":"26","author":"Linkous","year":"2019","journal-title":"Cell Rep"},{"key":"2026041704180186400_vdaf255-B101","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/s41551-019-0363-x","article-title":"A bioprinted human-glioblastoma-on-a-chip for the identification of patient-specific responses to chemoradiotherapy","volume":"3","author":"Yi","year":"2019","journal-title":"Nat Biomed Eng"},{"key":"2026041704180186400_vdaf255-B102","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s00401-020-02226-7","article-title":"Patient-derived organoids and orthotopic xenografts of primary and recurrent gliomas represent relevant patient avatars for precision oncology","volume":"140","author":"Golebiewska","year":"2020","journal-title":"Acta Neuropathol"},{"key":"2026041704180186400_vdaf255-B103","first-page":"vdad152","article-title":"Patient-derived glioblastoma organoids reflect tumor heterogeneity and treatment sensitivity","volume":"5","author":"Verduin","year":"2023","journal-title":"Neurooncol Adv"},{"key":"2026041704180186400_vdaf255-B104","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1158\/2159-8290.CD-23-1336","article-title":"Glioblastoma cortical organoids recapitulate cell-state heterogeneity and intercellular transfer","volume":"15","author":"Mangena","year":"2025","journal-title":"Cancer Discov"},{"key":"2026041704180186400_vdaf255-B105","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/j.stem.2025.07.003","article-title":"Chemical reprogramming of human blood cells to pluripotent stem cells","volume":"32","author":"Peng","year":"2025","journal-title":"Cell Stem Cell"},{"key":"2026041704180186400_vdaf255-B106","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1093\/neuonc\/noae184","article-title":"Brain tumoroids: treatment prediction and drug development for brain tumors with fast, reproducible, and easy-to-use personalized models","volume":"27","author":"Soub\u00e9ran","year":"2025","journal-title":"Neuro Oncol"},{"key":"2026041704180186400_vdaf255-B107","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1038\/s41591-023-02464-8","article-title":"Correcting the drug development paradigm for glioblastoma requires serial tissue sampling","volume":"29","author":"Singh","year":"2023","journal-title":"Nat Med"},{"key":"2026041704180186400_vdaf255-B108","doi-asserted-by":"crossref","first-page":"eadv2881","DOI":"10.1126\/scitranslmed.adv2881","article-title":"Serial multiomics uncovers anti-glioblastoma responses not evident by routine clinical analyses","volume":"17","author":"Ling","year":"2025","journal-title":"Sci Transl Med"},{"key":"2026041704180186400_vdaf255-B109","doi-asserted-by":"crossref","first-page":"825","DOI":"10.3390\/jpm11080825","article-title":"A critical review of radiation therapy: from particle beam therapy (proton, carbon, and BNCT) to beyond","volume":"11","author":"Matsumoto","year":"2021","journal-title":"J Pers Med"},{"key":"2026041704180186400_vdaf255-B110","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1148\/47.5.487","article-title":"Radiological use of fast protons","volume":"47","author":"Wilson","year":"1946","journal-title":"Radiology"},{"key":"2026041704180186400_vdaf255-B111","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.ijrobp.2021.05.126","article-title":"Joint optimization of photon & carbon ion treatments for glioblastoma","volume":"111","author":"Bennan","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026041704180186400_vdaf255-B112","doi-asserted-by":"crossref","first-page":"82","DOI":"10.3389\/fonc.2020.00082","article-title":"Carbon ion therapy: a modern review of an emerging technology","volume":"10","author":"Malouff","year":"2020","journal-title":"Front Oncol"},{"key":"2026041704180186400_vdaf255-B113","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/nrclinonc.2017.30","article-title":"Charged-particle therapy in cancer: clinical uses and future perspectives","volume":"14","author":"Durante","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"2026041704180186400_vdaf255-B114","doi-asserted-by":"crossref","first-page":"66","DOI":"10.3390\/cancers9060066","article-title":"Carbon ion radiotherapy: a review of clinical experiences and preclinical research, with an emphasis on DNA damage\/repair","volume":"9","author":"Mohamad","year":"2017","journal-title":"Cancers (Basel)"},{"key":"2026041704180186400_vdaf255-B115","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1053\/clon.2002.0185","article-title":"Particle beams for cancer therapy","volume":"15","author":"Weyrather","year":"2003","journal-title":"Clin Oncol"},{"key":"2026041704180186400_vdaf255-B116","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s13014-022-02187-z","article-title":"Charged particle therapy for high-grade gliomas in adults: a systematic review","volume":"18","author":"Wang","year":"2023","journal-title":"Radiat Oncol"},{"key":"2026041704180186400_vdaf255-B117","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ijrobp.2015.06.015","article-title":"Radiosensitivity of patient-derived glioma stem cell 3-Dimensional cultures to photon, proton, and carbon irradiation","volume":"95","author":"Chiblak","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026041704180186400_vdaf255-B118","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.123837","article-title":"Carbon irradiation overcomes glioma radioresistance by eradicating stem cells and forming an antiangiogenic and immunopermissive niche","volume":"4","author":"Chiblak","year":"2019","journal-title":"JCI Insight"},{"key":"2026041704180186400_vdaf255-B119","doi-asserted-by":"crossref","first-page":"454","DOI":"10.3109\/09553002.2013.766769","article-title":"Impact of carbon ion irradiation on epidermal growth factor receptor signaling and glioma cell migration in comparison to conventional photon irradiation","volume":"89","author":"Stahler","year":"2013","journal-title":"Int J Radiat Biol"},{"key":"2026041704180186400_vdaf255-B120","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3109\/09553002.2014.937511","article-title":"High resistance to X-rays and therapeutic carbon ions in glioblastoma cells bearing dysfunctional ATM associates with intrinsic chromosomal instability","volume":"91","author":"Dokic","year":"2015","journal-title":"Int J Radiat Biol"},{"key":"2026041704180186400_vdaf255-B121","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1080\/09553000802641151","article-title":"Radiobiological evaluation and correlation with the local effect model (LEM) of carbon ion radiation therapy and temozolomide in glioblastoma cell lines","volume":"85","author":"Combs","year":"2009","journal-title":"Int J Radiat Biol"},{"key":"2026041704180186400_vdaf255-B122","doi-asserted-by":"crossref","first-page":"692","DOI":"10.3109\/09553002.2013.791406","article-title":"Temozolomide in combination with carbon ion or photon irradiation in glioblastoma multiforme cell lines\u2014does scheduling matter?","volume":"89","author":"Harrabi","year":"2013","journal-title":"Int J Radiat Biol"},{"key":"2026041704180186400_vdaf255-B123","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.radonc.2013.06.026","article-title":"Comparison of carbon ion radiotherapy to photon radiation alone or in combination with temozolomide in patients with high-grade gliomas: Explorative hypothesis-generating retrospective analysis","volume":"108","author":"Combs","year":"2013","journal-title":"Radiother Oncol"},{"key":"2026041704180186400_vdaf255-B124","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.ijrobp.2007.03.003","article-title":"Phase I\/II clinical trial of carbon ion radiotherapy for malignant gliomas: combined X-Ray radiotherapy, chemotherapy, and carbon ion radiotherapy","volume":"69","author":"Mizoe","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026041704180186400_vdaf255-B125","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.radonc.2008.03.005","article-title":"Comparative evaluation of radiochemotherapy with temozolomide versus standard-of-care postoperative radiation alone in patients with WHO grade III astrocytic tumors","volume":"88","author":"Combs","year":"2008","journal-title":"Radiother Oncol"},{"key":"2026041704180186400_vdaf255-B126","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.ijrobp.2007.11.064","article-title":"Radiochemotherapy in patients with primary glioblastoma comparing two temozolomide dose regimens","volume":"71","author":"Combs","year":"2008","journal-title":"International Journal of Radiation OncologyBiologyPhysics"},{"key":"2026041704180186400_vdaf255-B127","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1007\/s00066-005-1359-x","article-title":"Temozolomide combined with irradiation as postoperative treatment of primary glioblastoma multiforme: Phase I\/II study","volume":"181","author":"Combs","year":"2005","journal-title":"Strahlenther Onkol"},{"key":"2026041704180186400_vdaf255-B128","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1186\/1471-2407-10-478","article-title":"Randomized phase II study evaluating a carbon ion boost applied after combined radiochemotherapy with temozolomide versus a proton boost after radiochemotherapy with temozolomide in patients with primary glioblastoma: the CLEOPATRA trial","volume":"10","author":"Combs","year":"2010","journal-title":"BMC Cancer"},{"key":"2026041704180186400_vdaf255-B129","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/0360-3016(93)90144-K","article-title":"Clinical results of fractionated proton therapy","volume":"25","author":"Tsujii","year":"1993","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026041704180186400_vdaf255-B130","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3171\/jns.1999.91.2.0251","article-title":"Accelerated fractionated proton\/photon irradiation to 90 cobalt gray equivalent for glioblastoma multiforme: results of a phase II prospective trial","volume":"91","author":"Fitzek","year":"1999","journal-title":"J Neurosurg"},{"key":"2026041704180186400_vdaf255-B131","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1016\/j.prro.2014.03.012","article-title":"Long-term survival after treatment of glioblastoma multiforme with hyperfractionated concomitant boost proton beam therapy","volume":"5","author":"Mizumoto","year":"2015","journal-title":"Pract Radiat Oncol"},{"key":"2026041704180186400_vdaf255-B132","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.radonc.2017.09.040","article-title":"Sequential proton boost after standard chemoradiation for high-grade glioma","volume":"125","author":"Adeberg","year":"2017","journal-title":"Radiother Oncol"},{"key":"2026041704180186400_vdaf255-B133","doi-asserted-by":"crossref","first-page":"2802","DOI":"10.1002\/cncr.32828","article-title":"Particle radiation therapy in the management of malignant glioma: early experience at the Shanghai proton and heavy ion center","volume":"126","author":"Kong","year":"2020","journal-title":"Cancer"},{"key":"2026041704180186400_vdaf255-B134","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1093\/neuonc\/noab040","article-title":"A prospective phase II randomized trial of proton radiotherapy vs intensity-modulated radiotherapy for patients with newly diagnosed glioblastoma","volume":"23","author":"Brown","year":"2021","journal-title":"Neuro Oncol"},{"key":"2026041704180186400_vdaf255-B135","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1093\/neuonc\/noaa182","article-title":"Proton therapy reduces the likelihood of high-grade radiation-induced lymphopenia in glioblastoma patients: phase II randomized study of protons vs photons","volume":"23","author":"Mohan","year":"2021","journal-title":"Neuro Oncol"},{"key":"2026041704180186400_vdaf255-B136","first-page":"1204","author":"Mehta","year":"2025"},{"key":"2026041704180186400_vdaf255-B137","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.radonc.2019.04.008","article-title":"Clinical translation of FLASH radiotherapy: why and how?","volume":"139","author":"Bourhis","year":"2019","journal-title":"Radiother Oncol"},{"key":"2026041704180186400_vdaf255-B138","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1038\/1831450a0","article-title":"Modification of the oxygen effect when bacteria are given large pulses of radiation","volume":"183","author":"Dewey","year":"1959","journal-title":"Nature"},{"key":"2026041704180186400_vdaf255-B139","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.radmp.2023.10.005","article-title":"The clinical prospect of FLASH radiotherapy","volume":"4","author":"Liu","year":"2023","journal-title":"Radiat Med Prot"},{"key":"2026041704180186400_vdaf255-B140","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines9020181","article-title":"Translational research in FLASH radiotherapy-from radiobiological mechanisms to in vivo results","volume":"9","author":"Marcu","year":"2021","journal-title":"Biomedicines"},{"key":"2026041704180186400_vdaf255-B141","doi-asserted-by":"crossref","first-page":"20190702","DOI":"10.1259\/bjr.20190702","article-title":"The FLASH effect depends on oxygen concentration","volume":"93","author":"Adrian","year":"2019","journal-title":"Br J Radiol"},{"key":"2026041704180186400_vdaf255-B142","doi-asserted-by":"crossref","first-page":"10943","DOI":"10.1073\/pnas.1901777116","article-title":"Long-term neurocognitive benefits of FLASH radiotherapy driven by reduced reactive oxygen species","volume":"116","author":"Montay-Gruel","year":"2019","journal-title":"Proc Natl Acad Sci USA"},{"key":"2026041704180186400_vdaf255-B143","doi-asserted-by":"crossref","first-page":"324","DOI":"10.2307\/3573572","article-title":"The radiosensitivity of cultured mammalian cells exposed to single high intensity pulses of electrons in various concentrations of oxygen","volume":"52","author":"Epp","year":"1972","journal-title":"Radiat Res"},{"key":"2026041704180186400_vdaf255-B144","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1080\/09553007414550901","article-title":"Oxygen depletion in cells irradiated at ultra-high dose-rates and at conventional dose-rates","volume":"26","author":"Weiss","year":"1974","journal-title":"Int J Radiat Biol Relat Stud Phys Chem Med"},{"key":"2026041704180186400_vdaf255-B145","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1042\/BJ20081258","article-title":"Increased levels of superoxide and H2O2 mediate the differential susceptibility of cancer cells versus normal cells to glucose deprivation","volume":"418","author":"Aykin-Burns","year":"2009","journal-title":"Biochem J"},{"key":"2026041704180186400_vdaf255-B146","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.radonc.2019.03.028","article-title":"An integrated physico-chemical approach for explaining the differential impact of FLASH versus conventional dose rate irradiation on cancer and normal tissue responses","volume":"139","author":"Spitz","year":"2019","journal-title":"Radiother Oncol"},{"key":"2026041704180186400_vdaf255-B147","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.radonc.2020.04.054","article-title":"Ultra-high dose rate effect on circulating immune cells: a potential mechanism for FLASH effect?","volume":"149","author":"Jin","year":"2020","journal-title":"Radiother Oncol"},{"key":"2026041704180186400_vdaf255-B148","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1016\/j.ijrobp.2020.11.012","article-title":"Effects of ultra-high doserate FLASH irradiation on the tumor microenvironment in lewis lung carcinoma: role of myosin light chain","volume":"109","author":"Kim","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026041704180186400_vdaf255-B149","doi-asserted-by":"crossref","first-page":"245ra93","DOI":"10.1126\/scitranslmed.3008973","article-title":"Ultrahigh dose-rate FLASH irradiation increases the differential response between normal and tumor tissue in mice","volume":"6","author":"Favaudon","year":"2014","journal-title":"Sci Transl Med"},{"key":"2026041704180186400_vdaf255-B150","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/s41392-025-02184-0","article-title":"Ultra-high dose rate radiotherapy overcomes radioresistance in head and neck squamous cell carcinoma","volume":"10","author":"Li","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"2026041704180186400_vdaf255-B151","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.radonc.2019.06.019","article-title":"Treatment of a first patient with FLASH-radiotherapy","volume":"139","author":"Bourhis","year":"2019","journal-title":"Radiother Oncol"},{"key":"2026041704180186400_vdaf255-B152","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1001\/jamaoncol.2022.5843","article-title":"Proton FLASH radiotherapy for the treatment of symptomatic bone metastases: the FAST-01 nonrandomized trial","volume":"9","author":"Mascia","year":"2023","journal-title":"JAMA Oncol"},{"key":"2026041704180186400_vdaf255-B153","first-page":"100743","article-title":"Randomized phase II selection trial of FLASH and conventional radiotherapy for patients with localized cutaneous squamous cell carcinoma or basal cell carcinoma: a study protocol","volume":"45","author":"Kinj","year":"2024","journal-title":"Clin Transl Radiat Oncol"},{"key":"2026041704180186400_vdaf255-B154","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1158\/1078-0432.CCR-20-0894","article-title":"Hypofractionated FLASH-RT as an effective treatment against glioblastoma that reduces neurocognitive side effects in mice","volume":"27","author":"Montay-Gruel","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2026041704180186400_vdaf255-B155","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.radonc.2018.08.016","article-title":"X-rays can trigger the FLASH effect: ultra-high dose-rate synchrotron light source prevents normal brain injury after whole brain irradiation in mice","volume":"129","author":"Montay-Gruel","year":"2018","journal-title":"Radiother Oncol"},{"key":"2026041704180186400_vdaf255-B156","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.radonc.2019.06.006","article-title":"Reduced cognitive deficits after FLASH irradiation of whole mouse brain are associated with less hippocampal dendritic spine loss and neuroinflammation","volume":"139","author":"Simmons","year":"2019","journal-title":"Radiother Oncol"},{"key":"2026041704180186400_vdaf255-B157","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.ijrobp.2022.12.018","article-title":"Proton FLASH radiation therapy and immune infiltration: evaluation in an orthotopic glioma rat model","volume":"116","author":"Iturri","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026041704180186400_vdaf255-B158","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1093\/neuonc\/noac248","article-title":"Elucidating the neurological mechanism of the FLASH effect in juvenile mice exposed to hypofractionated radiotherapy","volume":"25","author":"Allen","year":"2023","journal-title":"Neuro Oncol"},{"key":"2026041704180186400_vdaf255-B159","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1016\/j.ijrobp.2024.11.089","article-title":"FLASH Bragg-peak irradiation with a therapeutic carbon ion beam: first In vivo results","volume":"121","author":"Tinganelli","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026041704180186400_vdaf255-B160","doi-asserted-by":"crossref","first-page":"10602","DOI":"10.1038\/s41598-025-94534-9","article-title":"Effects of whole brain proton irradiation at conventional or ultra-high dose rate (FLASH), in adult male Sprague Dawley rats","volume":"15","author":"Williams","year":"2025","journal-title":"Sci Rep"},{"key":"2026041704180186400_vdaf255-B161","doi-asserted-by":"crossref","first-page":"1309174","DOI":"10.3389\/fonc.2023.1309174","article-title":"Comparable survival in rats with intracranial glioblastoma irradiated with single-fraction conventional radiotherapy or FLASH radiotherapy","volume":"13","author":"Liljedahl","year":"2023","journal-title":"Front Oncol"},{"key":"2026041704180186400_vdaf255-B162","doi-asserted-by":"crossref","first-page":"12285","DOI":"10.1038\/s41598-022-16612-6","article-title":"Long-term anti-tumor effects following both conventional radiotherapy and FLASH in fully immunocompetent animals with glioblastoma","volume":"12","author":"Liljedahl","year":"2022","journal-title":"Sci Rep"},{"key":"2026041704180186400_vdaf255-B163","doi-asserted-by":"crossref","first-page":"4912","DOI":"10.1002\/mp.15649","article-title":"Ultra-high dose rate dosimetry: challenges and opportunities for FLASH radiation therapy","volume":"49","author":"Romano","year":"2022","journal-title":"Med Phys"},{"key":"2026041704180186400_vdaf255-B164","doi-asserted-by":"crossref","first-page":"e70102","DOI":"10.1002\/acm2.70102","article-title":"Machine stability and dosimetry for ultra-high dose rate FLASH radiotherapy human clinical protocol","volume":"26","author":"Gon\u00e7alves Jorge","year":"2025","journal-title":"J Appl Clin Med Phys"},{"key":"2026041704180186400_vdaf255-B165","doi-asserted-by":"crossref","first-page":"105722","DOI":"10.4329\/wjr.v17.i4.105722","article-title":"Clinical translation of ultra-high dose rate flash radiotherapy: opportunities, challenges, and prospects","volume":"17","author":"Yang","year":"2025","journal-title":"World J Radiol"},{"key":"2026041704180186400_vdaf255-B166","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1038\/s41571-022-00697-z","article-title":"Towards clinical translation of FLASH radiotherapy","volume":"19","author":"Vozenin","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"2026041704180186400_vdaf255-B167","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1038\/s41571-022-00652-y","article-title":"Radiotheranostics in oncology: current challenges and emerging opportunities","volume":"19","author":"Bodei","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"2026041704180186400_vdaf255-B168","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1038\/s41571-025-01069-z","article-title":"The molecular blueprint of targeted radionuclide therapy","volume":"22","author":"Primac","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"key":"2026041704180186400_vdaf255-B169","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41420-023-01778-3","article-title":"Carrier systems of radiopharmaceuticals and the application in cancer therapy","volume":"10","author":"Zhang","year":"2024","journal-title":"Cell Death Discov"},{"key":"2026041704180186400_vdaf255-B170","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1007\/s13139-019-00618-6","article-title":"Radioimmunotherapy (RIT) in brain tumors","volume":"53","author":"Gholamrezanezhad","year":"2019","journal-title":"Nucl Med Mol Imaging"},{"key":"2026041704180186400_vdaf255-B171","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41573-020-0073-9","article-title":"Radiopharmaceutical therapy in cancer: clinical advances and challenges","volume":"19","author":"Sgouros","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"2026041704180186400_vdaf255-B172","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1080\/09553000802395535","article-title":"First human treatment of resistant neoplastic meningitis by intrathecal administration of MTX plus (125)IUdR","volume":"84","author":"Rebischung","year":"2008","journal-title":"Int J Radiat Biol"},{"key":"2026041704180186400_vdaf255-B173","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14143418","article-title":"Individualization of radionuclide therapies: challenges and prospects","volume":"14","author":"Piwowarska-Bilska","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2026041704180186400_vdaf255-B174","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1007\/s00259-023-06568-8","article-title":"Dosimetry for targeted radionuclide therapy in routine clinical practice: experts advice vs. clinical evidence","volume":"51","author":"Dieudonn\u00e9","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2026041704180186400_vdaf255-B175","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/B978-0-323-99873-4.00023-2","volume-title":"New Insights Into Glioblastoma","author":"Pinto","year":"2023"},{"key":"2026041704180186400_vdaf255-B176","doi-asserted-by":"crossref","first-page":"7911","DOI":"10.7150\/thno.56639","article-title":"A perspective on the radiopharmaceutical requirements for imaging and therapy of glioblastoma","volume":"11","author":"Bolcaen","year":"2021","journal-title":"Theranostics"},{"key":"2026041704180186400_vdaf255-B177","doi-asserted-by":"crossref","first-page":"1165747","DOI":"10.3389\/fmed.2023.1165747","article-title":"Targeted alpha particle therapy in oncology","volume":"10","author":"Bruland","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"2026041704180186400_vdaf255-B178","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-024-02041-6","article-title":"Radiopharmaceuticals and their applications in medicine","volume":"10","author":"Zhang","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"2026041704180186400_vdaf255-B179","first-page":"1973"},{"key":"2026041704180186400_vdaf255-B180","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s41181-019-0075-2","article-title":"Auger electrons for cancer therapy\u2014a review","volume":"4","author":"Ku","year":"2019","journal-title":"EJNMMI Radiopharm Chem"},{"key":"2026041704180186400_vdaf255-B181","doi-asserted-by":"crossref","first-page":"872","DOI":"10.3390\/ph14090872","article-title":"Peptide receptor radionuclide therapy and primary brain tumors: an overview","volume":"14","author":"Cimini","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"key":"2026041704180186400_vdaf255-B182","doi-asserted-by":"crossref","first-page":"167","DOI":"10.2967\/jnumed.123.266205","article-title":"Theranostics in neurooncology: heading toward new horizons","volume":"65","author":"Tolboom","year":"2024","journal-title":"J Nucl Med"},{"key":"2026041704180186400_vdaf255-B183","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s13052-018-0563-0","article-title":"Possible strategies to cross the blood\u2013brain barrier","volume":"44","author":"Bellettato","year":"2018","journal-title":"Ital J Pediatr"},{"key":"2026041704180186400_vdaf255-B184","doi-asserted-by":"crossref","first-page":"40391","DOI":"10.1021\/acsami.4c07850","article-title":"Targeted radionuclide therapy in glioblastoma","volume":"16","author":"Zhao","year":"2024","journal-title":"ACS Appl Mater Interfaces"},{"key":"2026041704180186400_vdaf255-B185","doi-asserted-by":"crossref","first-page":"S208","DOI":"10.1093\/neuonc\/noae125","article-title":"Targeted radionuclide therapy for gliomas: Emerging clinical trial landscape","volume":"26","author":"Weller","year":"2024","journal-title":"Neuro Oncol"},{"key":"2026041704180186400_vdaf255-B186","doi-asserted-by":"crossref","first-page":"22","DOI":"10.5301\/ijbm.5000301","article-title":"EGFR as a clinical marker in glioblastomas and other gliomas","volume":"33","author":"Saadeh","year":"2018","journal-title":"Int J Biol Markers"},{"key":"2026041704180186400_vdaf255-B187","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.3390\/ijms25042316","article-title":"Epidermal growth factor receptor inhibitors in glioblastoma: current status and future possibilities","volume":"25","author":"Ezzati","year":"2024","journal-title":"Int J Mol Sci"},{"key":"2026041704180186400_vdaf255-B188","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1038\/s41388-017-0045-7","article-title":"Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies","volume":"37","author":"An","year":"2018","journal-title":"Oncogene"},{"key":"2026041704180186400_vdaf255-B189","doi-asserted-by":"crossref","first-page":"197","DOI":"10.2174\/156800912799277557","article-title":"Targeting EGFR for treatment of glioblastoma: molecular basis to overcome resistance","volume":"12","author":"Taylor","year":"2012","journal-title":"Curr Cancer Drug Targets"},{"key":"2026041704180186400_vdaf255-B190","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1097\/01.COC.0000041009.06780.E5","article-title":"Radioiodinated (I-125) monoclonal antibody 425 in the treatment of high grade glioma patients: ten-year synopsis of a novel treatment","volume":"25","author":"Emrich","year":"2002","journal-title":"Am J Clin Oncol"},{"key":"2026041704180186400_vdaf255-B191","doi-asserted-by":"crossref","first-page":"192","DOI":"10.3171\/2010.2.JNS091211","article-title":"A phase II study of anti\u2013epidermal growth factor receptor radioimmunotherapy in the treatment of glioblastoma multiforme: clinical article","volume":"113","author":"Li","year":"2010","journal-title":"J Neurosurg"},{"key":"2026041704180186400_vdaf255-B192","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1089\/hyb.2006.25.125","article-title":"Use of monoclonal anti-EGFR antibody in the radioimmunotherapy of malignant gliomas in the context of EGFR expression in grade III and IV tumors","volume":"25","author":"Wygoda","year":"2006","journal-title":"Hybridoma (Larchmt)"},{"key":"2026041704180186400_vdaf255-B193","doi-asserted-by":"crossref","first-page":"300","DOI":"10.2967\/jnumed.116.177733","article-title":"Highly increased 125I-JR11 antagonist binding In vitro reveals novel indications for sst2 targeting in human cancers","volume":"58","author":"Reubi","year":"2017","journal-title":"J Nucl Med"},{"key":"2026041704180186400_vdaf255-B194","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 trial of (177)Lu-Dotatate for midgut neuroendocrine tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N Engl J Med"},{"key":"2026041704180186400_vdaf255-B195","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1002\/(SICI)1097-0215(19980529)76:5<620::AID-IJC2>3.0.CO;2-S","article-title":"Expression of somatostatin receptor subtypes in human brain tumors","volume":"76","author":"Dutour","year":"1998","journal-title":"Int J Cancer"},{"key":"2026041704180186400_vdaf255-B196","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1007\/s00432-018-2645-1","article-title":"Differential somatostatin, CXCR4 chemokine and endothelin a receptor expression in WHO grade I\u2013IV astrocytic brain tumors","volume":"144","author":"Lange","year":"2018","journal-title":"J Cancer Res Clin Oncol"},{"key":"2026041704180186400_vdaf255-B197","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1093\/jnen\/63.1.13","article-title":"Differential expression of sst1, sst2A, and sst3 somatostatin receptor proteins in low-grade and high-grade astrocytomas","volume":"63","author":"Mawrin","year":"2004","journal-title":"J Neuropathol Exp Neurol"},{"key":"2026041704180186400_vdaf255-B198","doi-asserted-by":"crossref","first-page":"397","DOI":"10.2967\/jnumed.109.072819","article-title":"Response of recurrent high-grade glioma to treatment with (90)Y-DOTATOC","volume":"51","author":"Heute","year":"2010","journal-title":"J Nucl Med"},{"key":"2026041704180186400_vdaf255-B199","doi-asserted-by":"crossref","first-page":"12860","DOI":"10.1038\/s41598-019-49009-z","article-title":"L-Type amino acid transporter 1 (LAT1\/Lat1)-utilizing prodrugs can improve the delivery of drugs into neurons, astrocytes and microglia","volume":"9","author":"Huttunen","year":"2019","journal-title":"Sci Rep"},{"key":"2026041704180186400_vdaf255-B200","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s13550-021-00865-9","article-title":"L-type amino acid transporter (LAT) 1 expression in (18)F-FET-negative gliomas","volume":"11","author":"Vettermann","year":"2021","journal-title":"EJNMMI Res"},{"key":"2026041704180186400_vdaf255-B201","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.nucmedbio.2010.12.002","article-title":"Validation of an amino-acid-based radionuclide therapy plus external beam radiotherapy in heterotopic glioblastoma models","volume":"38","author":"Israel","year":"2011","journal-title":"Nucl Med Biol"},{"key":"2026041704180186400_vdaf255-B202","first-page":"vdae130","article-title":"Results from a phase I study of 4-l-[131I]iodo-phenylalanine ([(131)I]IPA) with external radiation therapy in patients with recurrent glioblastoma (IPAX-1)","volume":"6","author":"Pichler","year":"2024","journal-title":"Neurooncol Adv"},{"key":"2026041704180186400_vdaf255-B203","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.18632\/oncotarget.27552","article-title":"Targeted alpha therapy using astatine ((211)At)-labeled phenylalanine: a preclinical study in glioma bearing mice","volume":"11","author":"Watabe","year":"2020","journal-title":"Oncotarget"},{"key":"2026041704180186400_vdaf255-B204","doi-asserted-by":"crossref","first-page":"212","DOI":"10.3413\/Nukmed-0580-13-05","article-title":"Systemic treatment with 4-211Atphenylalanine enhances survival of rats with intracranial glioblastoma","volume":"52","author":"Borrmann","year":"2013","journal-title":"Nuklearmedizin"},{"key":"2026041704180186400_vdaf255-B205","doi-asserted-by":"crossref","first-page":"971462","DOI":"10.3389\/fonc.2022.971462","article-title":"Matricellular protein tenascin C: implications in glioma progression, gliomagenesis, and treatment","volume":"12","author":"Fu","year":"2022","journal-title":"Front Oncol"},{"key":"2026041704180186400_vdaf255-B206","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1002\/1097-0142(19940201)73:3+<1076::AID-CNCR2820731347>3.0.CO;2-Z","article-title":"Intralesional radioimmunotherapy of malignant gliomas. An effective treatment in recurrent tumors","volume":"73","author":"Riva","year":"1994","journal-title":"Cancer"},{"key":"2026041704180186400_vdaf255-B207","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/ijc.2910510103","article-title":"Treatment of intracranial human glioblastoma by direct intratumoral administration of 131I-labelled anti-tenascin monoclonal antibody BC-2","volume":"51","author":"Riva","year":"1992","journal-title":"Int J Cancer"},{"key":"2026041704180186400_vdaf255-B208","doi-asserted-by":"crossref","first-page":"30","DOI":"10.2967\/jnumed.107.046938","article-title":"Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6","volume":"49","author":"Zalutsky","year":"2008","journal-title":"J Nucl Med"},{"key":"2026041704180186400_vdaf255-B209","first-page":"1042","article-title":"Dosimetry and radiographic analysis of 131I-Labeled anti\u2212tenascin 81C6 murine monoclonal antibody in newly diagnosed patients with malignant gliomas: a phase II study","volume":"46","author":"Akabani","year":"2005","journal-title":"J Nucl Med"},{"key":"2026041704180186400_vdaf255-B210","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1200\/JCO.2005.03.4082","article-title":"Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results","volume":"24","author":"Reardon","year":"2006","journal-title":"J Clin Oncol"},{"key":"2026041704180186400_vdaf255-B211","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1007\/s00259-023-06425-8","article-title":"EANM position paper: theranostics in brain tumours\u2014the present and the future","volume":"51","author":"Tolboom","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2026041704180186400_vdaf255-B212","doi-asserted-by":"crossref","first-page":"646387","DOI":"10.3389\/fonc.2021.646387","article-title":"PSMA expression in glioblastoma as a basis for theranostic approaches: a retrospective, correlational panel study including immunohistochemistry, clinical parameters and PET imaging","volume":"11","author":"Holzgreve","year":"2021","journal-title":"Front Oncol"},{"key":"2026041704180186400_vdaf255-B213","doi-asserted-by":"crossref","first-page":"e512","DOI":"10.1097\/RLU.0000000000003142","article-title":"177Lu-\/68Ga-PSMA theranostics in recurrent glioblastoma multiforme: proof of concept","volume":"45","author":"Kumar","year":"2020","journal-title":"Clin Nucl Med"},{"key":"2026041704180186400_vdaf255-B214","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s41181-024-00282-y","article-title":"Preclinical evaluation of CXCR4 peptides for targeted radionuclide therapy in glioblastoma","volume":"9","author":"Waked","year":"2024","journal-title":"EJNMMI Radiopharm Chem"},{"key":"2026041704180186400_vdaf255-B215","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s13139-023-00814-5","article-title":"Lu]Lu-DOTAGA.Glu.(FAPi)(2) Radionuclide therapy: a new treatment option for patients with glioblastoma multiforme","volume":"58","author":"Ballal","year":"2024","journal-title":"Nucl Med Mol Imaging"},{"key":"2026041704180186400_vdaf255-B216","first-page":"12","article-title":"PARADIGM-2: two parallel phase I studies of olaparib and radiotherapy or olaparib and radiotherapy plus temozolomide in patients with newly diagnosed glioblastoma, with treatment stratified by MGMT status","volume":"8","author":"Fulton","year":"2018","journal-title":"Clin Transl Radiat Oncol"},{"key":"2026041704180186400_vdaf255-B217","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1093\/neuonc\/noaa104","article-title":"Pharmacokinetics, safety, and tolerability of olaparib and temozolomide for recurrent glioblastoma: results of the phase I OPARATIC trial","volume":"22","author":"Hanna","year":"2020","journal-title":"Neuro Oncol"},{"key":"2026041704180186400_vdaf255-B218","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1158\/1078-0432.CCR-24-2974","article-title":"Olaparib, temozolomide, and concomitant radiotherapy for partially resected or biopsy-only glioblastoma first-line treatment: results from the OLA-TMZ-RTE-01 Phase I study","volume":"31","author":"Stefan","year":"2025","journal-title":"Clin Cancer Res"},{"key":"2026041704180186400_vdaf255-B219","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1093\/neuonc\/noab111","article-title":"A randomized phase II trial of veliparib, radiotherapy, and temozolomide in patients with unmethylated MGMT glioblastoma: the VERTU study","volume":"23","author":"Sim","year":"2021","journal-title":"Neuro Oncol"},{"key":"2026041704180186400_vdaf255-B220","doi-asserted-by":"crossref","first-page":"100107","DOI":"10.1016\/j.dmd.2025.100107","article-title":"Achieving human brain exposure with the oral ataxia-telangiectasia mutated kinase inhibitor AZD1390, a substrate of aldehyde oxidase","volume":"53","author":"Colclough","year":"2025","journal-title":"Drug Metab Dispos"},{"key":"2026041704180186400_vdaf255-B221","first-page":"S119","article-title":"Safety and preliminary efficacy of AZD1390 + radiation therapy for glioblastoma","volume-title":"Int J Radiat Oncol Biol Phys.","author":"Yang","year":"2024"},{"key":"2026041704180186400_vdaf255-B222","first-page":"e242","article-title":"A combined phase 0\/1b trial of ATM inhibitor AZD1390 in combination with radiation in patients with newly-diagnosed, MGMT-unmethylated glioblastoma","volume-title":"Int J Radiat Oncol Biol Phys.","author":"Kennedy","year":"2024"},{"key":"2026041704180186400_vdaf255-B223","doi-asserted-by":"crossref","first-page":"2992","DOI":"10.1158\/1535-7163.MCT-09-0463","article-title":"Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents","volume":"8","author":"Hirai","year":"2009","journal-title":"Mol Cancer Ther"},{"key":"2026041704180186400_vdaf255-B224","doi-asserted-by":"crossref","first-page":"3820","DOI":"10.1158\/1078-0432.CCR-17-3348","article-title":"Phase 0 trial of AZD1775 in first-recurrence glioblastoma patients","volume":"24","author":"Sanai","year":"2018","journal-title":"Clin Cancer Res"},{"key":"2026041704180186400_vdaf255-B225","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1038\/s41423-024-01226-x","article-title":"Immunotherapy for glioblastoma: current state, challenges, and future perspectives","volume":"21","author":"Liu","year":"2024","journal-title":"Cell Mol Immunol"},{"key":"2026041704180186400_vdaf255-B226","doi-asserted-by":"crossref","first-page":"Cns86","DOI":"10.2217\/cns-2021-0015","article-title":"Radiotherapy-drug combinations in the treatment of glioblastoma: a brief review","volume":"11","author":"McAleavey","year":"2022","journal-title":"CNS Oncol"},{"key":"2026041704180186400_vdaf255-B227","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/neuonc\/noac239","article-title":"Exploiting radiation immunostimulatory effects to improve glioblastoma outcome","volume":"25","author":"Awada","year":"2023","journal-title":"Neuro Oncol"},{"key":"2026041704180186400_vdaf255-B228","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1093\/neuonc\/noaa260","article-title":"Hypofractionated stereotactic re-irradiation with pembrolizumab and bevacizumab in patients with recurrent high-grade gliomas: results from a phase I study","volume":"23","author":"Sahebjam","year":"2021","journal-title":"Neuro Oncol"},{"key":"2026041704180186400_vdaf255-B229","doi-asserted-by":"crossref","first-page":"4467","DOI":"10.1002\/cncr.31662","article-title":"Clinical trials involving carbon-ion radiation therapy and the path forward","volume":"124","author":"Lazar","year":"2018","journal-title":"Cancer"},{"key":"2026041704180186400_vdaf255-B230","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.addr.2016.11.006","article-title":"Proton therapy\u2014present and future","volume":"109","author":"Mohan","year":"2017","journal-title":"Adv Drug Deliv Rev"},{"key":"2026041704180186400_vdaf255-B231","doi-asserted-by":"crossref","first-page":"5745","DOI":"10.1002\/mp.16586","article-title":"3D-conformal very-high energy electron therapy as candidate modality for FLASH-RT: a treatment planning study for glioblastoma and lung cancer","volume":"50","author":"B\u00f6hlen","year":"2023","journal-title":"Med Phys"},{"key":"2026041704180186400_vdaf255-B232","doi-asserted-by":"crossref","first-page":"644400","DOI":"10.3389\/fonc.2021.644400","article-title":"FLASH radiotherapy: history and future","volume":"11","author":"Lin","year":"2021","journal-title":"Front Oncol"},{"key":"2026041704180186400_vdaf255-B233","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1053\/j.semnuclmed.2019.11.004","article-title":"225Ac- and 213Bi-substance P analogues for glioma therapy","volume":"50","author":"Kr\u00f3licki","year":"2020","journal-title":"Semin Nucl Med"}],"container-title":["Neuro-Oncology Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/noa\/advance-article-pdf\/doi\/10.1093\/noajnl\/vdaf255\/65803888\/vdaf255.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/noa\/article\/doi\/10.1093\/noajnl\/vdaf255\/8374221","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/noa\/article\/doi\/10.1093\/noajnl\/vdaf255\/8374221","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T08:18:53Z","timestamp":1776413933000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/noa\/article\/doi\/10.1093\/noajnl\/vdaf255\/8374221"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,8]]},"references-count":233,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,12]]}},"URL":"https:\/\/doi.org\/10.1093\/noajnl\/vdaf255","relation":{},"ISSN":["2632-2498"],"issn-type":[{"value":"2632-2498","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1]]},"published":{"date-parts":[[2025,12,8]]},"article-number":"vdaf255"}}